Key statistics
On Friday, Cytodyn Inc (296:STU) closed at 0.195, 21.88% above the 52 week low of 0.16 set on Dec 29, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.195 |
|---|---|
| High | 0.202 |
| Low | 0.195 |
| Bid | 0.195 |
| Offer | 0.26 |
| Previous close | 0.20 |
| Average volume | 49.31k |
|---|---|
| Shares outstanding | 1.27bn |
| Free float | 1.27bn |
| P/E (TTM) | -- |
| Market cap | 312.52m USD |
| EPS (TTM) | -0.0322 USD |
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Announcements
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
- December 2025 Letter to Shareholders
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
- CytoDyn Announces Resolution of Class Action Lawsuit
- CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
- CytoDyn Secures $30 Million Commitment from Yorkville Advisors
- CytoDyn to Present at the LD Micro Main Event XIX Investor Conference
- September 2025 Letter to Shareholders
- CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
- CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
More ▼
